Real Estate - Development
Compare Stocks
4 / 10Stock Comparison
SGD vs LGND vs PRGO vs GREE
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Drug Manufacturers - Specialty & Generic
Financial - Capital Markets
SGD vs LGND vs PRGO vs GREE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Real Estate - Development | Biotechnology | Drug Manufacturers - Specialty & Generic | Financial - Capital Markets |
| Market Cap | $155K | $4.13B | $1.61B | $19M |
| Revenue (TTM) | $5M | $251M | $4.18B | $60M |
| Net Income (TTM) | $-14M | $49M | $-1.82B | $-2M |
| Gross Margin | 16.6% | 85.9% | 34.2% | 79.7% |
| Operating Margin | -186.2% | 7.0% | -4.1% | -19.2% |
| Forward P/E | — | 24.6x | 5.5x | — |
| Total Debt | $10M | $7M | $3.97B | $68M |
| Cash & Equiv. | $296K | $72M | $532M | $9M |
SGD vs LGND vs PRGO vs GREE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 23 | Feb 26 | Return |
|---|---|---|---|
| Safe and Green Deve… (SGD) | 100 | 0.6 | -99.4% |
| Ligand Pharmaceutic… (LGND) | 100 | 320.6 | +220.6% |
| Perrigo Company plc (PRGO) | 100 | 44.5 | -55.5% |
| Greenidge Generatio… (GREE) | 100 | 31.5 | -68.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SGD vs LGND vs PRGO vs GREE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SGD is the clearest fit if your priority is growth.
- 27.7% FFO/revenue growth vs GREE's -15.4%
LGND carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 27.3%, EPS growth -107.5%, 3Y rev CAGR -11.6%
- 73.0% 10Y total return vs GREE's -62.9%
- Lower volatility, beta 0.99, Low D/E 0.9%, current ratio 8.93x
- Beta 0.99, current ratio 8.93x
PRGO is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Better valuation composite
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
GREE lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.7% FFO/revenue growth vs GREE's -15.4% | |
| Value | Better valuation composite | |
| Quality / Margins | 19.3% margin vs SGD's -277.3% | |
| Stability / Safety | Beta 0.99 vs GREE's 3.33 | |
| Dividends | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +99.1% vs SGD's -80.4% | |
| Efficiency (ROA) | 3.3% ROA vs SGD's -35.9%, ROIC -2.3% vs -50.6% |
SGD vs LGND vs PRGO vs GREE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SGD vs LGND vs PRGO vs GREE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LGND leads in 4 of 6 categories
PRGO leads 2 • SGD leads 0 • GREE leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
LGND leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 840.6x SGD's $5M. LGND is the more profitable business, keeping 19.3% of every revenue dollar as net income compared to SGD's -2.8%. On growth, SGD holds the edge at +42.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $5M | $251M | $4.2B | $60M |
| EBITDAEarnings before interest/tax | -$9M | $52M | $58M | $4M |
| Net IncomeAfter-tax profit | -$14M | $49M | -$1.8B | -$2M |
| Free Cash FlowCash after capex | -$3M | $31M | $108M | -$20M |
| Gross MarginGross profit ÷ Revenue | +16.6% | +85.9% | +34.2% | +79.7% |
| Operating MarginEBIT ÷ Revenue | -186.2% | +7.0% | -4.1% | -19.2% |
| Net MarginNet income ÷ Revenue | -2.8% | +19.3% | -43.5% | -33.2% |
| FCF MarginFCF ÷ Revenue | -52.9% | +12.2% | +2.6% | -37.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +42.3% | +122.8% | -7.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +57.1% | +15.6% | -56.4% | +2.3% |
Valuation Metrics
PRGO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than LGND's 322.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $155,445 | $4.1B | $1.6B | $19M |
| Enterprise ValueMkt cap + debt − cash | $10M | $4.1B | $5.1B | $79M |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | -956.05x | -1.14x | -0.65x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.64x | 5.53x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 322.10x | 7.42x | 38.86x |
| Price / SalesMarket cap ÷ Revenue | 0.75x | 24.74x | 0.38x | 0.32x |
| Price / BookPrice ÷ Book value/share | 0.18x | 4.63x | 0.55x | — |
| Price / FCFMarket cap ÷ FCF | — | 53.41x | 11.12x | — |
Profitability & Efficiency
LGND leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
LGND delivers a 5.1% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-7 for SGD. LGND carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to SGD's 11.95x. On the Piotroski fundamental quality scale (0–9), SGD scores 5/9 vs GREE's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.0% | +5.1% | -50.7% | — |
| ROA (TTM)Return on assets | -35.9% | +3.3% | -19.8% | -3.2% |
| ROICReturn on invested capital | -50.6% | -2.3% | +3.7% | -57.2% |
| ROCEReturn on capital employed | -3.1% | -2.7% | +4.3% | -23.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 4 | 3 |
| Debt / EquityFinancial leverage | 11.95x | 0.01x | 1.35x | — |
| Net DebtTotal debt minus cash | $10M | -$65M | $3.4B | $59M |
| Cash & Equiv.Liquid assets | $296,202 | $72M | $532M | $9M |
| Total DebtShort + long-term debt | $10M | $7M | $4.0B | $68M |
| Interest CoverageEBIT ÷ Interest expense | -1.89x | 22.69x | -7.20x | 0.70x |
Total Returns (Dividends Reinvested)
LGND leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LGND five years ago would be worth $16,102 today (with dividends reinvested), compared to $13 for SGD. Over the past 12 months, LGND leads with a +99.1% total return vs SGD's -80.4%. The 3-year compound annual growth rate (CAGR) favors LGND at 39.5% vs SGD's -89.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -14.9% | +10.6% | -13.5% | -25.6% |
| 1-Year ReturnPast 12 months | -80.4% | +99.1% | -51.2% | +29.0% |
| 3-Year ReturnCumulative with dividends | -99.9% | +171.6% | -58.1% | -71.0% |
| 5-Year ReturnCumulative with dividends | -99.9% | +61.0% | -60.1% | -99.2% |
| 10-Year ReturnCumulative with dividends | -99.9% | +73.0% | -77.7% | -62.9% |
| CAGR (3Y)Annualised 3-year return | -89.1% | +39.5% | -25.2% | -33.8% |
Risk & Volatility
LGND leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LGND is the less volatile stock with a 0.99 beta — it tends to amplify market swings less than GREE's 3.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LGND currently trades 85.0% from its 52-week high vs SGD's 6.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.57x | 1.03x | 1.21x | 3.37x |
| 52-Week HighHighest price in past year | $2.36 | $247.38 | $28.44 | $2.42 |
| 52-Week LowLowest price in past year | $0.11 | $98.89 | $9.23 | $0.87 |
| % of 52W HighCurrent price vs 52-week peak | +6.9% | +85.0% | +41.2% | +50.4% |
| RSI (14)Momentum oscillator 0–100 | 40.0 | 59.3 | 60.9 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 0 | 226K | 3.4M | 138K |
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: LGND as "Buy", PRGO as "Hold". Consensus price targets imply 208.9% upside for PRGO (target: $36) vs 27.3% for LGND (target: $268). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | — |
| Price TargetConsensus 12-month target | — | $267.75 | $36.20 | — |
| # AnalystsCovering analysts | — | 17 | 36 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | +9.8% | — |
| Dividend StreakConsecutive years of raises | — | 1 | 10 | — |
| Dividend / ShareAnnual DPS | — | — | $1.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
LGND leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook).
SGD vs LGND vs PRGO vs GREE: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SGD or LGND or PRGO or GREE a better buy right now?
For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.
3% revenue growth year-over-year, versus -15. 4% for Greenidge Generation Holdings Inc. (GREE). Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SGD or LGND or PRGO or GREE?
Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +61.
0%, compared to -99. 9% for Safe and Green Development Corporation (SGD). Over 10 years, the gap is even starker: LGND returned +82. 2% versus SGD's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SGD or LGND or PRGO or GREE?
By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 1.
03β versus Greenidge Generation Holdings Inc. 's 3. 37β — meaning GREE is approximately 228% more volatile than LGND relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 12% for Safe and Green Development Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — SGD or LGND or PRGO or GREE?
By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.
3% versus -15. 4% for Greenidge Generation Holdings Inc. (GREE). On earnings-per-share growth, the picture is similar: Greenidge Generation Holdings Inc. grew EPS 57. 6% year-over-year, compared to -21. 2% for Safe and Green Development Corporation. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SGD or LGND or PRGO or GREE?
Ligand Pharmaceuticals Incorporated (LGND) is the more profitable company, earning -2.
4% net margin versus -42. 9% for Safe and Green Development Corporation — meaning it keeps -2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -31. 6% for SGD. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SGD or LGND or PRGO or GREE more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
5x forward P/E versus 24. 6x for Ligand Pharmaceuticals Incorporated — 19. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.
07Which pays a better dividend — SGD or LGND or PRGO or GREE?
In this comparison, PRGO (9.
8% yield) pays a dividend. SGD, LGND, GREE do not pay a meaningful dividend and should not be held primarily for income.
08Is SGD or LGND or PRGO or GREE better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
21), 9. 8% yield). Greenidge Generation Holdings Inc. (GREE) carries a higher beta of 3. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, GREE: -62. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SGD and LGND and PRGO and GREE?
These companies operate in different sectors (SGD (Real Estate) and LGND (Healthcare) and PRGO (Healthcare) and GREE (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SGD is a small-cap quality compounder stock; LGND is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; GREE is a small-cap quality compounder stock. PRGO pays a dividend while SGD, LGND, GREE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.